Education
About Us
Working with TipRanks
Follow Us
Knight Therapeutics (KHTRF)
:KHTRF
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
<0.01Last Year’s EPS
-0.03Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 20, 2025
|% Change Since: -2.98%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Neutral
Knight Therapeutics reported record revenues and significant pipeline expansion but faced challenges with declining gross margins, decreased adjusted EBITDA, and competition from generic products. The acquisition of Paladin and new contracts in Brazil are positive, but these are offset by currency and hyperinflation challenges.Company Guidance
During Knight Therapeutics' Fourth Quarter 2024 conference call on March 20, 2025, significant guidance was provided for fiscal 2025. The company anticipates revenue between $390 million to $405 million and expects adjusted EBITDA to be approximately 13% of revenues. This forecast assumes the successful mid-2025 closure of the Paladin transaction, which is expected to add $70 million in revenue and includes an upfront payment of $100 million plus $20 million for inventory. Knight's 2024 financial results showcased record high revenues exceeding $365 million and an adjusted EBITDA of about $58 million. The promoted portfolio, comprising 75% of total revenues, grew by 16% over the previous year, with a three-year CAGR exceeding 30%. The company also expanded its pipeline with five new products and secured several regulatory submissions and approvals, expecting these developments to generate peak sales of over $150 million. Knight's ongoing product launches and growth investments are aimed at maintaining its strong performance trajectory.Record-Breaking Revenue and Growth
Knight Therapeutics delivered 11 years of consecutive record high revenues, achieving over $365 million in revenue and approximately $58 million in adjusted EBITDA for 2024. The promoted portfolio grew by 16% over the prior year period and has delivered a three-year CAGR of more than 30%.
Pipeline Expansion
Significant progress was made in expanding the pipeline with five new products. The company now has a pipeline of 18 products expected to generate peak sales of over $150 million.
Regulatory Approvals
Obtained several regulatory approvals, including Minjuvi and TAVALISSE in Mexico and Jornay PM in Canada. Also launched two products in Canada, Bijuva and Imvexxy.
Acquisition of Paladin
Entered into an agreement to acquire all assets of Paladin, adding a portfolio of stable cash flow-generating products, with expected revenues of $70 million for 2024.
New MOH Contract in Brazil
Signed a new contract for AmBisome with the Ministry of Health in Brazil, expecting to deliver approximately $22.4 million in 2025.
---
KHTRF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
KHTRF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 20, 2025 | $4.36 | $4.39 | +0.69% |
| Nov 07, 2024 | $4.11 | $3.73 | -9.25% |
| Aug 08, 2024 | $4.01 | $4.19 | +4.49% |
| May 09, 2024 | $4.30 | $4.47 | +3.95% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Knight Therapeutics (KHTRF) report earnings?
Knight Therapeutics (KHTRF) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Knight Therapeutics (KHTRF) earnings time?
Knight Therapeutics (KHTRF) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KHTRF EPS forecast?
KHTRF EPS forecast for the fiscal quarter 2025 (Q1) is <0.01.
---